Switzerland · Series B startup

Who invested in GlycoEra

One round we have observed, with the 9 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcarePharma

Funding summaryUpdated 5 Nov 2026

$130Mraised across 1 round since 2025, from 1 source

Latest round
Series B, $130MMay 2025
Led by
Novo Holdings
Investors
9 (1 led)
See who backed them

The rounds

  1. May 2025

Founders and team

From GlycoEra's own website: 3 on the team.

  • Andrea MatthewsChief Business Officer
  • Colleen GrahamSVP, Head of Clinical Operations
  • Max KlementBoard Member

Everyone who backed them

Novo HoldingsVC firm1round, led 1
Sofinnova PartnersVC firm1round
5AM VenturesVC firm1round
M VenturesCorporate VC1round
Roche VenturesGrowth equity1round
LifeArc VenturesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about GlycoEra

Who invested in GlycoEra?

GlycoEra's investors include Novo Holdings, Sofinnova Partners, 5AM Ventures, M Ventures and Catalio Capital Management, and 4 more on record. Novo Holdings led its latest round.

How much has GlycoEra raised?

GlycoEra has raised $130M across 1 round since 2025.

When did GlycoEra last raise?

GlycoEra's most recent round was a Series B of $130M in May 2025, led by Novo Holdings.

What was GlycoEra's biggest round?

Its most recent round, $130M in May 2025, is also its largest on record.

Who backed GlycoEra first?

GlycoEra's first round on record, in May 2025, was backed by Novo Holdings, Sofinnova Partners and 5AM Ventures and 6 others.

What stage is GlycoEra at?

GlycoEra's latest named round is a Series B, in May 2025.

Where is GlycoEra based?

GlycoEra is based in Switzerland.

Who led GlycoEra's rounds?

Novo Holdings led the Series B in 2025.

Companies like GlycoEra

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.